Last reviewed · How we verify

NCT06955624: OMID-NEURO

Use of Omics Methods to Classify Variations of Uncertain Significance and Improve Diagnosis of Neurogenetic Diseases

Recruiting now NA Last updated 2 May 2025
What this trial tests

NA trial testing RNA and/or DNA methylation and/or protein analysis in Neurogenetic Diseases in 95 participants. Currently enrolling.

Timeline
15 January 2025
Primary endpoint
15 January 2030
15 January 2031

Quick facts

Lead sponsorUniversity Hospital, Rouen
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment95
Start date15 January 2025
Primary completion15 January 2030
Estimated completion15 January 2031
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Rouen

Who can join

Eligibility, any sex, with Neurogenetic Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Many neurological disorders show a strong genetic basis, from hereditary diseases caused by a single mutation in a given gene, to diseases caused by combinations of strong genetic risk factors. However, even after the sequencing of the appropriate genes, a large proportion of patients remains undiagnosed, either because there is no candidate mutation observed, or in case of identification of a candidate mutation with insufficient knowledge to consider it as pathogenic or not. The aim of this project is to identify the cause of neurogenetic diseases in patients in situations of diagnostic wandering or dead ends by proposing the analysis of RNA and/or proteins from different tissues.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Rouen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06955624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing